MarketCapExport financials
Surgalign Holdings (SRGA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Surgalign Holdings Income Statement 2022-2011 | SRGA
Brief overview of financial results at Surgalign Holdings
The overview follows changes across a five-year period. The revenue attributed to Surgalign Holdings moved from $90.3 million to $82 million between the two endpoints. The cumulative result was −9.2%, corresponding to roughly −1.9% per year. The business did not achieve meaningful top-line expansion.
Gross profit changed from $53.8 million to $40.3 million (−25.2%). The relationship between sales and direct costs deteriorated. Comparing the endpoints gives gross margins of 59.6% and 49.1%. The contraction points to pressure from direct costs or weaker pricing power.
Over the period, EBITDA shifted from −48.4 million dollars to −76.3 million dollars, a change of −57.5%. Operating performance weakened relative to revenue. EBITDA margin moved from −53.7% to −93%. A lower EBITDA share weakens the quality of the result.
The net financial result changed from 6.9 million dollars to −54.6 million dollars. The business lost profitability by the end of the period.
Market value was 7.8 billion dollars at the start and 11.4 million dollars at the end. Market value lagged the financial performance.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The weaker side of the profile includes a softer top-line trend, lower investor confidence and a weaker final result. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Surgalign Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
11.4 M | 84.6 M | 3.75 B | 8.75 B | 8.04 B | 7.79 B | 5.68 B | 185 M | 253 M | 177 M | 251 M | 220 M |
Shares |
6.56 M | 4.09 M | 74.4 M | 70.2 M | 61 M | 57.7 M | 58.2 M | 57.6 M | 56.7 M | 56.3 M | 55.9 M | 55.2 M |
Historical Prices |
1.74 | 20.7 | 50.4 | 125 | 132 | 135 | 97.5 | 96.3 | 134 | 93 | 148 | 104 |
Net Income |
-54.6 M | -84.7 M | -33.8 M | -212 M | -3.12 M | 6.91 M | -13.8 M | 14.9 M | 2.7 M | -17.8 M | 8.4 M | 8.38 M |
Revenue |
82 M | 90.5 M | 102 M | 117 M | 92.1 M | 90.3 M | 276 M | 282 M | 263 M | 198 M | 178 M | 169 M |
Cost of Revenue |
41.7 M | 29.8 M | 44 M | 32.8 M | 33.6 M | 36.4 M | 143 M | - | - | - | - | - |
Gross Profit |
40.3 M | 60.7 M | 57.7 M | 84.6 M | 58.5 M | 53.8 M | 133 M | 150 M | 134 M | 80.1 M | 85.2 M | 77.2 M |
Operating Income |
-78.5 M | -137 M | -198 M | -243 M | -64.8 M | -62.7 M | -15.3 M | - | - | - | - | - |
Interest Expense |
1.01 M | 202 K | 61 K | 12.6 M | 2.77 M | 3.18 M | 1.66 M | - | - | - | - | - |
EBITDA |
-76.3 M | -135 M | -191 M | -220 M | -50.2 M | -48.4 M | 1.27 M | 43.8 M | 26 M | -4.57 M | 22.6 M | 19.8 M |
Operating Expenses |
120 M | 202 M | 256 M | 328 M | 123 M | 117 M | 149 M | 123 M | 123 M | 96.9 M | 70.6 M | 65.4 M |
General and Administrative Expenses |
95.9 M | 104 M | 124 M | 135 M | 98.2 M | 90.8 M | 117 M | - | 4.8 M | - | 20 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Surgalign Holdings
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
8.07 M | 7.86 M | 6.74 M | 6.64 M | 172 M | 4.89 M | 138 M | 114 M | 98.1 M | 81.7 M | 73.2 M | 75.8 M | 75.8 M | 75.2 M | 75.2 M | 75.1 M | 65.7 M | 63.5 M | 63.5 M | 63.4 M | 63.2 M | 62.7 M | 60.5 M | 59.4 M | 58.5 M | - | 57.4 M | 58 M | 58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
4.14 M | - | -9.83 M | -5.69 M | 27 K | - | -7.91 M | -16.2 M | -15.2 M | -100 M | 123 M | -38.6 M | -17.9 M | -197 M | -4.85 M | 744 K | -9.09 M | 799 K | 3 M | -5.8 M | -1.12 M | -7.23 M | 17.7 M | -1.66 M | -1.88 M | - | -3.5 M | -1.68 M | 2.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
16.7 M | - | 20.2 M | 20.6 M | 20.6 M | - | 20.5 M | 24.8 M | 23.3 M | 26.2 M | 27.9 M | 54.2 M | 73.7 M | 31.6 M | 76.1 M | 82.3 M | 69.7 M | 23.1 M | 24.1 M | 22.4 M | 22.5 M | 71.1 M | 67.2 M | 71.6 M | 70.4 M | - | 66.5 M | 69.9 M | 67.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
6.07 M | - | 5.49 M | 6.41 M | 6.41 M | - | 6.81 M | 7.23 M | 6.24 M | - | 11.9 M | 31.1 M | 33.3 M | - | 34.6 M | 37.6 M | 31.7 M | - | 32.2 M | 40.5 M | 35.6 M | - | 33.4 M | 34.9 M | 34.2 M | - | 32.4 M | 35 M | 31.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
10.7 M | - | 14.7 M | 14.2 M | 14.2 M | - | 13.7 M | 17.6 M | 17.1 M | 12.8 M | 16 M | 23.1 M | 40.5 M | 23.5 M | 41.5 M | 44.7 M | 38 M | 17.2 M | 17.9 M | 8.99 M | 14.4 M | 36.4 M | 33.8 M | 36.7 M | 36.2 M | - | 34.1 M | 34.9 M | 35.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.14 M | - | -8 M | -13.4 M | -8.92 M | - | -16.9 M | -13.3 M | -14.4 M | - | -26.7 M | -23.5 M | -17.6 M | - | -3.1 M | 1.52 M | -7.19 M | - | 4.91 M | -7.46 M | -167 K | - | 34.6 M | 386 K | -1.97 M | - | -3.57 M | -1.73 M | 3.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
252 K | - | 252 K | 252 K | 252 K | - | 117 K | 101 K | - | - | 21 K | 5.97 M | 3.56 M | - | 3.72 M | 3.64 M | 1.6 M | - | 611 K | 777 K | 835 K | - | 741 K | 915 K | 819 K | - | 308 K | 392 K | 361 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-644 K | - | -6.26 M | -12.2 M | -8.36 M | - | -15.1 M | -12.1 M | -13.9 M | - | -20.7 M | -18.8 M | -15.4 M | - | 8.31 M | 9.01 M | -3.49 M | - | 15.7 M | -396 K | 3.42 M | - | 34.6 M | 386 K | 1.6 M | - | -3.57 M | -1.73 M | 8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
24.4 M | - | 23.6 M | 27.6 M | 23.1 M | - | 34.6 M | 30.9 M | 31.5 M | - | 42.7 M | 46.6 M | 58.1 M | - | 44.6 M | 43.2 M | 45.2 M | - | 33.3 M | 37.4 M | 33.7 M | - | -780 K | 36.3 M | 38.2 M | - | 37.6 M | 36.7 M | 32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
21.1 M | - | 23.9 M | 24.3 M | 25.3 M | - | 27.6 M | 25.5 M | 25.9 M | - | 27.8 M | 37.1 M | 39.2 M | - | 37.1 M | 39 M | 31.9 M | - | 29.7 M | 29.3 M | 28.4 M | - | 1.82 M | 29.6 M | 29.7 M | - | 28.8 M | 28.4 M | 27.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Surgalign Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |